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Abstract
The earliest immune responses activated in acute human immunodeficiency virus type 1 infection (AHI) exert a critical
influence on subsequent virus spread or containment. During this time frame, components of the innate immune system
such as macrophages and DCs, NK cells, b-defensins, complement and other anti-microbial factors, which have all been
implicated in modulating HIV infection, may play particularly important roles. A proteomics-based screen was performed on
a cohort from whom samples were available at time points prior to the earliest positive HIV detection. The ability of selected
factors found to be elevated in the plasma during AHI to inhibit HIV-1 replication was analyzed using in vitro PBMC and DC
infection models. Analysis of unique plasma donor panels spanning the eclipse and viral expansion phases revealed very
early alterations in plasma proteins in AHI. Induction of acute phase protein serum amyloid A (A-SAA) occurred as early as 5–
7 days prior to the first detection of plasma viral RNA, considerably prior to any elevation in systemic cytokine levels.
Furthermore, a proteolytic fragment of alpha–1-antitrypsin (AAT), termed virus inhibitory peptide (VIRIP), was observed in
plasma coincident with viremia. Both A-SAA and VIRIP have anti-viral activity in vitro and quantitation of their plasma levels
indicated that circulating concentrations are likely to be within the range of their inhibitory activity. Our results provide
evidence for a first wave of host anti-viral defense occurring in the eclipse phase of AHI prior to systemic activation of other
immune responses. Insights gained into the mechanism of action of acute-phase reactants and other innate molecules
against HIV and how they are induced could be exploited for the future development of more efficient prophylactic vaccine
strategies.
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Introduction
Although human immunodeficiency virus type 1 (HIV-1) induces
a chronic infection ultimately culminating in the development of an
acquired immunodeficiency syndrome, it is now recognized that
critical damage to the host immune system is mediated during the
acute phase of infection, when an exponential burst of viral
replication takes place, associated with massive depletion of the
central memory CD4
+ T cell pool [1,2]. Prophylactic strategies to
combat HIV-1 infection thus need to modulate events in the earliest
stages of infection leading up to and impacting on this acute viral
burst – which prompts an urgent need to understand the virus-host
interactions occurring during this ‘‘window of opportunity’’.
Adaptive responses are known to play an important role in
containment of the acute burst of viral replication in AHI [3], but
events in the earliest stages of infection are also likely to be heavily
influenced by components of the innate immune system [3]. These
include cellular determinants of the efficiency of viral entry into
and replication within host cells such as the CCR5-delta32 allele,
CCR2, CCL5 (RANTES), CX(3)CR1, CXCL12, or TRIM5, all
of which can influence host resistance or susceptibility to HIV
infection [3]. Interaction of virions with dendritic cells (DCs) early
after virus transmission can have outcomes including virion
destruction (following binding to langerin on resting Langerhans
cells), efficient viral transmission to CD4+ T cells (following
binding to DC-SIGN on sub-epithelial DCs), or the triggering of
DCs (via interaction with TLRs) to produce cytokines/chemokines
that may mediate antiviral activity, but may also drive immuno-
pathological immune activation including cellular apoptosis [4,5].
Genetic studies have helped to cast light on the in vivo importance
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HIV infection. These include associations between expression of
certain KIRs and their cognate HLA alleles and resistance to,
and/or control of HIV replication, implicating NK cells in control
of HIV replication [6,7,8]. Furthermore, b-defensins, secreted
from oral and mucosal epithelial cells appear to inhibit HIV-1
infection [9]. More recently, a peptide fragment derived from
alpha–1 antitrypsin (AAT), a serine protease inhibitor and acute
phase protein present in blood plasma, was shown to inhibit HIV
host cell infection by blocking gp41 mediated cell entry [10].
Other natural factors exist that modulate HIV infection, such as a
proteolytic product of the prostate phosphatase that is present in
semen, which has the ability to dramatically enhance HIV
infection [11].
Much of our current picture of events in the eclipse and earliest
viremic phases of acute HIV-1 infection is derived from in vitro
studies and work carried out in non-human primate simian
immunodeficiency virus (SIV) infection models, as the critical
initial stages of infection are very difficult to study in humans. The
availability of plasma sample series collected over a time-frame
spanning the eclipse and viral expansion phase of HIV infection
provide a unique opportunity to gain insight into the systemic
activation of immune responses during this time. Previous reports
have quantified an array of cytokines and markers of apoptosis in
plasma panels and described a massive systemic ‘‘cytokine storm’’
occurring during the viral ramp-up phase, associated with an
increase in plasma levels of apoptotic microparticles [12,13,14].
Importantly however, no systemic elevation in apoptosis markers
or cytokine levels was detected during the eclipse phase when virus
is being amplified at local infection sites prior to systemic
dissemination. In this study, we used a proteomics-based approach
combined with biochemical and cell biological assays to
characterize factors that are elevated in plasma during the earliest
stages of acute HIV-1 infection in humans. We describe increases
in plasma levels of acute-phase reactants and proteolytically
processed fragments that have anti-HIV activity during the eclipse
phase prior to detection of HIV viremia or the first increases in
systemic cytokine levels, which may represent the earliest systemic
host antiviral response activated following infection.
Results
Elevated plasma levels of acute phase markers in AHI
prior to detection of viremia
Samples collected at sequential time points spanning the eclipse
and viral ramp-up phases from 19 US plasma donors who
acquired HIV-1 infection were studied to gain insight into the
kinetics of the earliest systemic anti-viral defenses activated in the
acute phase of infection. Plasma was typically obtained from each
donor at intervals of 2–5 d. Plasma panels were tested for HIV-1
by RT-PCR analysis of viral RNA titers, and time courses from
different donors were aligned relative to the time point (T0) when
viremia first reached levels detectable by conventional assays
(.100 RNA copies ml
21; Fig. 1A). Most panels covered a time-
frame from around d 220 to d +20 relative to T0. It is currently
thought that the eclipse phase in HIV-1 infection is in the range of
7–10 d [12,15] hence most panels likely included samples collected
from time points prior to the acquisition of infection onwards.
In order to determine whether there are detectable changes in
plasma proteins or peptides accompanying the emergence of
viremia, an initial mass spectrometry-based screen was performed
on three plasma donor panels (Fig. 1B). Analysis of the
longitudinal MALDI-TOF data revealed mass peaks that were
elevated at viremic time points (Fig. 2A). One mass peak with a
molecular mass of 2178 Dalton [M+H]
+ was found to be
considerably elevated in HIV-1-positive plasma (Fig. 2A). Se-
quencing by MALDI-TOF/TOF and LC-MS/MS identified this
mass as peptide 86–105 derived from A-SAA (Fig. 2B and Fig.
S1A). A semi-quantitative analysis of mass peak intensities of the
2178Da [M+H]
+ peptide mass revealed that this peptide was
elevated coincident with the increase in viremia, and in 2 of the 3
subjects, immediately prior to the detection of viremia (Fig. 2C),
suggesting that A-SAA protein levels are elevated at these times. A
second mass peak with a molecular mass of 2213 Dalton [M+H]
+
was identified as peptide 960–979 of complement C3 (Fig. S1B).
This peak was also elevated prior to as well as during viremia
(Fig. 2C).
Plasma levels of A-SAA are increased prior to and during
detection of viremia in AHI
A-SAA was shown previously to be elevated in patients with
AIDS [16], and is commonly used as a general marker for
inflammation [17,18]. A recent study demonstrated that A-SAA
has anti-viral activity in vitro [19]. We therefore examined a larger
set of plasma donor panels (19) by ELISA to test whether elevation
of A-SAA levels may be a general feature associated with acute
HIV-1 infection, and how its induction is related to the increase in
plasma viral RNA titers. As a control and to establish a baseline for
use in statistical analysis of the data, we also measured A-SAA
levels in plasma panels from five control plasma donors who did
not become infected with HIV (Fig. S2A). Baseline levels of A-
SAA (calculated as described in the methods section) varied
between individuals and were generally between 600–3800ng/ml.
Analysis of A-SAA levels in the plasma panels from HIV-infected
donors confirmed that A-SAA was elevated relative to baseline
prior to and/or concurrent within the earliest detection of viremia.
Importantly, significant A-SAA elevations (i.e. falling above a 90%
prediction interval) were observed prior to T0 (viral RNA .100
copies ml
21) in 15 out of 19 subjects (Fig. 3A). In the subject
group as a whole, A-SAA levels were thus elevated significantly
prior to T0, the time of first detection of plasma viremia (p=0.02,
as determined using a Binomial test).
To monitor alterations of the acute form (A-SAA) as well as the
constitutively expressed form (C-SAA) of serum amyloid A, we
Author Summary
Acquired immune deficiency syndrome (AIDS) remains a
major health problem worldwide, affecting predominantly
the adult population in the western world and in
developing countries in particular. Despite a tremendous
effort to develop a cure or a vaccine that confers
protection against human immunodeficiency virus (HIV-1)
infection, this has not been achieved in a satisfactory
manner to date. Recent research efforts have suggested
that the earliest immune responses activated after
exposure to the virus have an influence on virus spread,
containment and disease progression. In this study, a
panel of donors who provided plasma samples collected
over a time-frame spanning the period before and
immediately after detection of HIV-1 infection permitted
an insight into the activation of the earliest systemic
immune responses. We describe increases in plasma levels
of acute-phase reactants and proteolytically processed
fragments that have anti-viral activity in vitro. These
inductions occur prior to detection of HIV-1 virus in the
blood and before the first increases in systemic cytokine
levels, which may represent the earliest systemic host
antiviral response activated following infection.
Rapid Systemic Acute Phase Anti-HIV-1 Response
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In 4 out of 10 plasma donor panels tested by immunoblotting
(9011, 9013, 9016 and 9018), we confirmed the initial increase in
A-SAA levels prior to viral ramp-up. In addition to this first wave
of A-SAA induction that occurred prior to detection of viremia,
immunoblotting also confirmed a second, more intense phase of
elevation, observed in six of the ten donors tested (9011, 9012,
9016, 9018, 64012, 64122) that coincided with the increase in viral
load. Other individuals either had very low or consistently high
levels of A-SAA over the time-frame analyzed. By contrast to A-
SAA, a major acute phase reactant that is inducible during the
infection process, C-SAA, which was observed in an unmodified
and glycosylated form, was detected with only minor inductions in
all panels examined. To further explore whether elevation of A-
SAA was specifically attributable to HIV-1 infection, we examined
6 plasma panels from donors who became positive either for
hepatitis C virus (HCV) or hepatitis B virus (HBV) during the
period of sample collection [14]. We detected increased levels of
A-SAA over the time course of infection in 1/3 panels from
subjects with acute HBV infection and 3/3 panels from subjects
with acute HCV infection (Fig. 3C and Fig. S2 B and C),
indicating that A-SAA induction may represent a common host
response to microbial infection.
Detection of AAT-derived VIRIP in AHI
A more comprehensive analysis by liquid chromatography
tandem mass spectrometry (LC-MS/MS) revealed a number of
other plasma components including complement factors, apo-
lipoproteins and alpha-1-antitrypsin (AAT) that are present in
plasma during AHI (Table S1). The factors found to be elevated
in plasma during AHI included a C-terminal peptide derived from
AAT, residues 377–396, referred to as VIRIP (Table S1 and
Fig. 4A), which was shown to inhibit HIV-1 entry into host cells
by targeting the gp41 fusion peptide [10]. Seven plasma panels
from HIV-infected individuals and five panels from uninfected
controls were evaluated for the presence of VIRIP by tandem mass
spectrometry in a semi-quantitative fashion. Ion counts detected
for the precursor ion representing the expected molecular mass of
VIRIP were correlated to viremia, and revealed an elevation of
VIRIP coincident with and after the initial increase in viremia in
two of the seven plasma donor panels from infected individuals,
but none in the five controls (Fig. 4B). A semi-quantitative
titration of VIRIP peptide by mass spectrometry indicated that the
amount detected corresponds to an estimated value of 0.1–0.3mM
of VIRIP in plasma at peak concentrations (Fig. 4C). Considering
the sample loss during the isolation of VIRIP peptide from plasma,
the effective VIRIP concentration will likely be in the range of low
mg/ml, which is approximating the IC50 value at which VIRIP
interferes with HIV-1 entry [10] (see also below).
VIRIP is a proteolytic fragment of AAT generated by
matrix metalloprotease (MMP)-mediated degradation
The appearance of VIRIP in plasma samples from HIV-1-
infected subjects raised the question of how proteolytic processing
of AAT may be mediated under these conditions. Previous studies
indicated that MMPs (collagenases and elastases) interact with and
cleave AAT [20]. Inspection of the regions of AAT flanking the
VIRIP sequence predicted cleavage sites for MMP-1, -6, -7, -8, -9,
-12, and MMP-26 at the N-terminal, and MMP-7 at the C-
terminal end of VIRIP (Fig. 5A). In vitro digestion of purified AAT
with recombinant MMP-7 revealed a degradation product at
5 kDa detectable by immunoblotting consistent with the C-
terminal AAT fragment 377–418 containing VIRIP (Fig. 5B).
Subsequent analysis was carried out using LC-MS/MS, which
identified peptides containing both cleavage sites required for the
formation of VIRIP at Phe376-Leu377 and Phe396-Leu397 (Fig. 5C).
A third cleavage within the VIRIP sequence at Pro381-Met382 was
also observed. Importantly, formation of VIRIP itself was detected
at the 2 h time point, confirming MMP-7 as a candidate protease
involved in generation of the peptide in vivo.
Figure 1. Characterization of plasma panels obtained from HIV-1-infected subjects. (A) Serial plasma HIV-1 RNA titers in the 19 US plasma
donors acquiring HIV infection used in this study. The sample time courses are aligned relative to a common time origin, T0, defined as the time point
when the plasma viral load first reached 100 RNA copies ml
21 as described in [14]. (B) Scheme representing the strategy for plasma sample
preparation and analysis by mass spectrometry.
doi:10.1371/journal.ppat.1000893.g001
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AHI
In order to test for potential interference with the infection
process we evaluated the ability of acute phase proteins AAT, A-
SAA and C-reactive protein (CRP) and the C-terminal AAT
fragments 397–418 and 377–396 (VIRIP) to inhibit HIV-1
replication using in vitro peripheral blood mononuclear cell
(PBMC) and dendritic cell (DC) infection models. PHA-activated
PBMCs or monocyte-derived dendritic cells (MDDCs) were
incubated with the test analytes both prior to and during infection
with either an R5- or an X4-tropic virus and subsequent HIV-1
replication was monitored by the analysis of supernatant p24 levels
or reverse transcriptase activity. VIRIP, derived from near the C-
terminus of AAT, markedly inhibited the replication of both the
R5 and the X4 virus, consistent with previous findings [10]
(Fig. 6A). In contrast, no effect was observed with either full-
length AAT or the C-terminal 22mer 398–418 (Fig. 6A). In
addition, CRP did not inhibit the replication of either the R5 or
the X4 virus in PBMCs (Fig. 6C). A-SAA did not exhibit any
inhibitory activity in the PBMC infection system, but did inhibit
the replication of the R5 virus in MDDCs as early as 12–24 h after
infection (Fig. S3) and to a greater extent after 7 d (Fig. 6B).
Importantly, inhibition of MDDC infection was still greater than
50% at a 1mgml
21 A-SAA concentration, which is well in the
range of the levels detected in infected individuals (Fig. 3A). A-
SAA was recently reported to inhibit MDDC infection by an X4/
R5 dual tropic virus via down-regulation of CCR5 expression
[19]. We conclude that components of the acute phase response
indeed have the capacity to interfere with HIV-1 infection,
thereby potentially helping to control viral dissemination in the
eclipse phase.
Discussion
The availability of sequential samples from plasma donors who
became infected with HIV-1 provides a unique opportunity to
study changes in plasma in the eclipse and viral expansion phases
of acute infection. Recent studies described the induction of a
‘‘cytokine storm’’ and massive cellular apoptosis during the phase
of exponential viral replication [12,13,14]. Here a proteomics-
driven approach was used to demonstrate for the first time that
acute phase proteins, some of which exhibit antiviral activity, are
induced systemically even prior to the first detection of viremia
and also before any detectable increase in plasma cytokine levels.
The factors elevated included A-SAA, a protein primarily
synthesized by cells in the liver, high-level production of which
is known to be induced during the acute phase response to
infection, trauma or stress by pro-inflammatory cytokines
including TNF-alpha, IL-6 and IL-22 [21]. Notably, A-SAA was
frequently elevated with biphasic kinetics in the plasma of subjects
acquiring HIV-1 infection, an initial elevation occurring during
the eclipse phase and a second elevation during the viral ramp-up
phase. The latter was temporally coincident with elevations in
circulating levels of multiple pro-inflammatory cytokines [14] and
likely reflected a hepatic response to this systemic stimulus. The
initial elevation in plasma A-SAA levels was found to occur
significantly prior to detection of viral RNA in the plasma, well
before any systemic elevations are detected in plasma cytokine/
chemokine levels [14]. Following sexual transmission of HIV-1,
virus replicates in the local genital or rectal mucosa, then spreads
to the draining lymph nodes and subsequently to the gut-
associated lymphoid tissue (GALT) [22]. The mechanism by
which acute phase protein production is triggered during this
process is currently unknown, but it may involve transfer of
inductive factors to the liver (including pro-inflammatory cytokines
produced at local sites of viral replication), triggering production of
acute phase reactants prior to widespread virus dissemination and
systemic increases in cytokine levels. Alternatively, A-SAA can be
produced at extra hepatic sites: A-SAA expression has been
reported in macrophages, adrenal glands, kidney and intestine,
albeit at lower levels as compared to hepatocytes [17]. The initial
burst of A-SAA levels may also contribute to the subsequent
‘‘cytokine storm’’ observed later at the systemic level, since A-SAA
was shown to induce an array of immunomodulatory cytokines
including of the Th1-type in monocytes, macrophages and
lymphocytes [23,24].
Activation of acute phase reactants may represent a very early
line of anti-viral defense in HIV-1 infection, since A-SAA, AAT
and a C-terminal peptide derived from AAT (referred to as
VIRIP) were each shown to exert anti-viral activity in vitro
[10,19,25,26] (Fig. 6A,B). However, not all acute phase proteins
that are induced in response to inflammation have anti-viral
properties as was observed with CRP (Fig. 6C), which was also
elevated systemically in plasma of some donors prior to viremia
(data not shown). We found selective inhibition of HIV-1 infection
of MDDCs but not PBMCs by A-SAA. Its ability to inhibit HIV-1
replication was previously proposed to be mediated by down-
regulation of CCR5 expression [19]. The capacity to inhibit R5
virus replication in MDDCs but not PBMCs may thus be due to
the fact that MDDCs express only low levels of CCR5, whereas
CCR5 expression on CD4
+ T cells is much higher. It is unlikely
that the inhibitory effects of A-SAA are limited to specific
pathogens only, as this acute phase reactant was described to be
up-regulated in a number of pathological processes [17] including
inflammation and diverse bacterial and viral infections [27,28,29].
Consistent with this, we observed marked elevation of A-SAA in
plasma panels from donors acutely-infected with HCV. Notably,
A-SAA has been shown to mediate antiviral activity against this
viral pathogen too, an effect proposed to be mediated by
mechanisms distinct from its inhibitory effect on HIV-1 infection
[30,31]. In acute HCV infection, A-SAA induction may be
stimulated as a consequence of viral replication in the liver, and
the associated cytokine response. In acute HBV infection little A-
SAA elevation was observed. This may relate to the different
Figure 2. Identification of plasma proteins present at elevated levels prior to or during acute HIV-1 viremia by mass spectrometry.
(A) Analysis of serial samples derived from plasma panel 64012 by MALDI-TOF mass spectrometry. Mass profiling reveals peaks (indicated by arrows
in the insert) that are observed uniquely in HIV-1 RNA-positive (after T0, indicated in red, data for time points +11 and +13 days are shown) as
compared to HIV-1 RNA-negative plasma samples (before T0, indicated in blue, data for time points 223 and 218 days are shown). (B) MALDI-TOF
LIFT (MS/MS) spectrum of precursor ion mass 2178 Da [M+H]
+ that was identified as the peptide 86–105 derived from human A-SAA (Swissprot
accession nr. P02735). Identified b- and y- fragment ions are indicated. (C) MALDI-TOF-based mass profiling of three plasma panels (64012, 9018 and
9034) revealed an elevation of peaks 2178 Da (peptide 86–105 from A-SAA) and 2213 Da (peptide 960–979 from complement C3, see Fig. S1) before
and during viremia. Viral load and T0 are as described previously [14]. Top panels: viral load; second and third panels: peak intensities of mass peaks
2178 Da and 2213 Da normalized to the corresponding peak intensities observed for the first time point of 64012; bottom panels: relative peak
intensities of mass peaks 1555 and 2552 that were used as standards, illustrating use of comparable MS acquisition conditions for all time points. The
arrows in the middle and bottom panels indicate viremic time points.
doi:10.1371/journal.ppat.1000893.g002
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PLoS Pathogens | www.plospathogens.org 5 May 2010 | Volume 6 | Issue 5 | e1000893Figure 3. Kinetic analysis of A-SAA levels prior to and during HIV-1 viremia. (A) A-SAA levels as measured by ELISA in plasma panels from
19 donors acquiring HIV-1 infection. In each graph, time is plotted relative to T0, plasma HIV RNA levels (log10 copies ml
21) are indicated by the open
circles and are as reported previously [14]. The solid circles show A-SAA protein levels. Subject-specific background levels of A-SAA (dotted grey lines)
and the 90% prediction interval (threshold for defining a significant elevation, black lines) were calculated as described in the methods section. 15 out
of 19 subjects show a significantly elevated A-SAA level before the first detectable viral load. (B). A-SAA and C-SAA protein levels in sequential plasma
samples from 10 donors acquiring HIV-1 infection as assessed using anti-A-SAA and anti-C-SAA immunoblotting. The two sets of blots are positioned
Rapid Systemic Acute Phase Anti-HIV-1 Response
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and/or the relatively muted cytokine response activated in acute
HBV infection [14].
Genetic studies suggest that polymorphisms observed in AAT,
another component of the acute phase response, are linked to
susceptibility to HIV-1 infection [32,33]. AAT was initially
reported to block the activity of HIV-1 protease [26,34,35].
Subsequently, an AAT-derived 26mer C-terminal peptide was
shown to inhibit HIV-1 LTR gene expression in vitro [36,37].
However, the strongest effect reported so far is exerted by VIRIP
generated as a proteolytic product from AAT, which inhibits viral
entry by binding to the gp41 fusion peptide and is active in the low
micromolar range [10]. For both A-SAA and VIRIP, we were able
to detect endogenous levels in plasma that are in the range capable
of mediating viral inhibition, which raises the possibility that such
factors play a role in combating viral replication, particularly in
the earliest stages of infection.
No strong correlation was found between the initial timing of A-
SAA elevation and either R0 (the viral reproductive rate), the slope
of viral ramp-up or the highest recorded viral load in the 19
subjects studied here. Nevertheless, the relationship between the
magnitude and dynamics of early acute-phase protein production
and the acute viral burst and subsequent efficiency of control of
viremia should be addressed in a future study on a larger cohort
from whom samples were collected over a longer time-frame
extending into early infection. Interestingly, we also noted that
levels of AAT proteolytic fragments in plasma from subjects
chronically-infected with HIV-1 were elevated as compared to
those in healthy controls (data not shown), suggesting that acute
phase proteins may also play a role in chronic viral infection. It is
possible that components of the acute phase response may not only
contribute to the control of viral replication in infected individuals,
but may also be involved in mediating resistance to infection. For
instance, HIV-1-exposed uninfected individuals have been shown
to have elevated levels of cleaved forms of A-SAA [19], which
suggests that their anti-viral activity contributes to resistance
against infection.
Evidence from the literature and our own data suggest that
MMPs are responsible for AAT proteolysis, in particular MMP-7,
MMP-9 and MMP-26 [38,39]. Altered levels of MMP-9 have
been reported to correlate with HIV-1 infection, and breakdown
of extracellular matrix has been suggested to aid dissemination of
the virus [40,41]. Our in vitro experiments confirmed the known
MMP-7 cleavage sites on the C-terminal part of AAT and also
demonstrated that VIRIP can be generated despite presence of an
additional cleavage site within the sequence of the peptide. This
cleavage site between Pro381-Met382, directly neighbouring the
active site Ser383, has been shown previously to be sensitive to the
oxidation state of the Met382 residue [42], thereby protecting
VIRIP from further degradation. In addition, our results support
the notion that the biological function of cleavage of AAT by
MMP-7 may not solely be inactivation of its serine protease
function, but also to generate new proteolytic peptides that have
additional activities in themselves.
The abundant acute phase proteins that we were able to detect
elevations in during AHI may be only selected examples of
constitutively-produced or inducible analytes that play a role in
combating infections. There is an increasing amount of evidence
suggesting that ‘‘endogenous factors’’ exist that have inherent
inhibitory activity towards infectious pathogens [43]. These
include antimicrobial polypeptides [44] and antiproteases such
as cystatins that have also been detected in cervical mucosa [45].
Insights gained into the mechanism of action of innate factors and
acute phase reactants against HIV-1 and how they can be induced
should be considered for novel vaccine strategies and therapeutics.
Materials and Methods
Ethics statement
Plasmapheresis samples from the US plasma donor cohort used
in this study were purchased from Zeptometrix Corporation and
SeraCare Life Sciences. Donors were recruited via the SeptaCare
Special Donor Program and enrolled for plasma donation after a
medical examination and an interview with medical staff, in which
it was explained that the donated plasma will be used by dedicated
drug and vaccine researchers to perform research to help others.
This study was approved by the Oxford Tropical Research Ethics
committee (OXTREC, University of Oxford) and the NIH Office
of Extramural Research (Nr. 201029 to B.M.K).
Plasma samples and viral load analysis
Panels of sequential samples obtained by plasmapheresis from
US plasma donors who became infected with HIV-1, HBV or
HCV and control subjects were purchased from Zeptometrix
Corporation and SeraCare Life Sciences and were stored at
280uC before use. Details of the panels and methods used for
analysis of HIV-1, HBV and HCV viral loads are as described
[14]. Each plasma panel included samples collected prior to
detection of plasma viremia through to seroconversion. The
plasma panels from HIV-infected individuals were temporally
aligned relative to a common time origin (T0), defined as the time
point when the viral load first reached detectable levels (.100 viral
RNA copies ml
21), as described previously [14]. The median and
range duration of observation prior to the first detectable HIV
RNA level (T0) for the 19 panels used in this study was 21 days
with a range of 7 to 58 days.
Sample preparation for analysis by mass spectrometry
Plasma donor samples were fractionated using weak anion
exchange (WAX) magnetic beads (Bruker Daltonics, Bremen,
Germany) according to the manufacturer’s recommendation (Text
S1).
Analysis by MALDI-TOF/TOF and LC-MS/MS tandem mass
spectrometry
For analysis by MALDI-TOF/TOF, a solution of a-cyano-4-
hydroxycinnamic acid (matrix, 3 mg) in ethanol:acetone (10 ml,
2:1) was prepared freshly. Samples processed as described above
and matrix solution were mixed in a ratio of 1:4, and 1 mL aliquots
were spotted in triplicates on an Anchor Chip MALDI plate
(Bruker Daltonics, Bremen, Germany). Data was acquired on an
UltraFlex MALDI-TOF/TOF instrument (Bruker Daltonics,
Bremen, Germany) at 60% laser power until a total intensity of
2610
5 ion counts was reached. Spectra were analyzed using
Bruker Daltonics FlexAnalysis software (version 2.4). For LC-MS/
MS tandem mass spectrometry, analysis was carried out by
so that the time point when plasma viral RNA was first detected is aligned (vertical line). Post-viremic time points are indicated by the horizontal
arrow. (C) A-SAA and C-SAA protein levels in sequential plasma samples from 3 donors acquiring HCV infection (top panel) and 3 donors acquiring
HBV infection (bottom panel). As above, the two sets of blots are positioned so that the time point when plasma viral nucleic acids were first detected
is aligned (vertical line); and post-viremic time points are indicated by the horizontal arrow.
doi:10.1371/journal.ppat.1000893.g003
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PLoS Pathogens | www.plospathogens.org 7 May 2010 | Volume 6 | Issue 5 | e1000893Figure 4. Tandem mass spectrometry-based detection of the antiviral peptide VIRIP, derived from the C-terminus of AAT, in plasma
during AHI. (A) MS/MS spectrum of precursor ion peptide 773.75 Da [M(ox)+3H]
3+ identified as VIRIP 377–396 derived from AAT (Swissprot
accession nr P01009) as detected in plasma panel 9012 (time point 5 d post-T0). Identified b- and y- fragment ions are shown. (B) LC-MS/MS based
detection of the VIRIP precursor ion 773.75 Da [M(ox)+3H]
3+ in plasma panels 63229 and 9012. Mass peak ion counts are shown in black, and viremic
time points are indicated by the grey arrow. (C) Quantitation of synthetic VIRIP peptide by LC-MS/MS indicates that the amount of VIRIP detected in
plasma is in the low micromolar range.
doi:10.1371/journal.ppat.1000893.g004
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nanoAcquity UPLC system coupled to a Waters Q-TOF Premier
tandem mass spectrometer in MS
E (high/low collision switching)
mode as described previously [46]. Processing of raw data was
performed using the ProteinLynx Global Server 2.2.5 software and
the data were interrogated on an in-house MASCOT server
(version 2.2). Alternatively, samples were analyzed on a Bruker
HCTplus Ion Trap tandem mass spectrometer (Bruker Daltonics,
Bremen, Germany) as described [47]. Semi-quantitative analysis
of MS data was based on measuring peak heights observed for the
peptide masses that were assigned to A-SAA86–105 [M+H]
+
2178Da, C3960–979 [M+H]
+ 2213Da (analysis by MALDI-TOF)
and VIRIP377–396 [M+3H]
3+ (methionine oxidized form)
773.75Da (analysis by LC-MS/MS). Seven plasma donor panels
of infected individuals (61 time points total) and five uninfected
control plasma donor panels (40 time points total) were examined.
For an approximate estimation of VIRIP quantities in plasma,
synthetic VIRIP was synthesized using Fmoc chemistry based
solid-phase peptide synthesis on an automated synthesizer
(Advanced ChemTech, Louisville, KY, USA) and different
concentrations measured by LC-MS/MS by monitoring the
[M+3H]
3+ precursor ion intensities under the same conditions
used for the analysis of plasma samples. It should be noted that
sample loss during plasma sample processing may lead to an
underestimation of the effective VIRIP concentration in plasma.
In vitro digestion of AAT by MMP-7
Recombinant active MMP-7 (EMD Biosciences, Gibbstown,
NJ) (7.2 mg, 4 ml) was added to a solution of AAT (Sigma Aldrich,
St. Louis, MO) (100 ml, 2.9 mg ml
21) in 100 mM ammonium
bicarbonate buffer and the mixture was incubated at 37uC.
Aliquots (5 ml) were removed for immunoblotting at 0, 5, 20, 60
and 120 min, mixed with RSB (5 ml) and retained for analysis.
Immunoblotting was carried out following gel electrophoresis on
4–12% Bis-Tris or 16% Tris–Tricine gels (Invitrogen, Carlsbad,
CA) for increased resolution of low molecular weight species. LC-
MS/MS analysis was carried out with the 5 min and 120 min time
point samples following desalting and concentration by methanol
chloroform precipitation [48].
ELISA assays
Analysis of plasma samples using an anti-SAA ELISA assay was
performed using a commercial SAA ELISA kit (Abazyme,
Needham, MA) and conducted according to the manufacturer’s
instructions. Plasma samples were diluted with assay buffer to
obtain final concentrations within the linear range of the assay of
1–80 ng ml
21. Inclusion of recombinant protein standards
demonstrated that A-SAA was sensitively detected by the assay
while C-SAA was non-reactive up to final concentrations of
750 ng ml
21.
HIV-1 inhibition assays
HIV-1 infection assays used viruses derived from the infectious
molecular clones pNL4.3-BaL.ecto (R5-tropic) and pNL4.3 (X4-
tropic), supplied by John Kappes and Christina Jambor (University
of Alabama at Birmingham, USA). Cryopreserved healthy donor
PBMCs were stimulated with 2.5ug ml
21 PHA (Sigma Aldrich, St.
Louis, MO) for 2 d in R10 medium (Invitrogen, Carlsbad, CA)
and 1 d with 50U ml2
1 IL-2 (Roche, Nutley, NJ) in R10 medium
adjusted to contain 20% serum. MDDCs were generated by
culturing CD14
+ cells isolated from buffy coats (National Blood
Service, London, UK) using a Human Monocyte Isolation Kit II
Figure 5. Proteolytic processing of AAT by MMP-7 generates VIRIP in vitro. (A) Potential MMP cleavage sites located in the C-terminal part
of AAT (370–418) as predicted by the MEROPS database (http://merops.sanger.ac.uk/). (B) In vitro degradation of AAT by MMP-7 reveals distinct
degradation intermediate fragments. Purified AAT was incubated with recombinant MMP-7 at the indicated concentrations and times, followed by
SDS-PAGE separation on a 4–12% Bis-Tris gel and immunoblotting using an anti-VIRIP antibody. (C) Prolonged incubation of AAT with MMP-7
resulted in the generation of the VIRIP peptide as well as AAT C-terminal fragments; Upper panel: 16% Tris-Tricine SDS-PAGE separation followed by
immunoblotting using an anti-VIRIP antibody; lower panel: LC-MS/MS analysis after 2 h digestion followed by database searching using the MASCOT
algorithm identifies C-terminal AAT peptides including VIRIP (AAT 377–396) as proteolysis products.
doi:10.1371/journal.ppat.1000893.g005
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21 IL-4
and 100ng ml
21 granulocyte-macrophage colony stimulating
factor (GM-CSF) (eBioscience, San Diego, CA). The proportion
of CD14
loCD11c
hi MDDC was typically 95%. Inhibitors included
CRP (ProSpec-Tany TechnoGene LTD., Rehovot, Israel), AAT
(Sigma, Gillingham, UK), A-SAA (MBL International, Woburn,
MA), VIRIP and the 22 amino acid AAT fragment C-terminal to
this peptide (both synthesized by Fmoc chemistry as described
above). CRP, AAT and A-SAA were dissolved in serum-free
OptiMEM (Invitrogen, Carlsbad, CA), VIRIP and the 22 amino
acid AAT fragment were dissolved in DMSO (Sigma-Aldrich, St.
Louis, MO) and diluted to a 2% solution in OptiMEM. Inhibitors
were diluted into cell culture medium to give the indicated final
concentrations. The final concentration of DMSO in the culture
Figure 6. Components of the acute phase response interfere with HIV-1 infection in vitro. (A) Effect of AAT or its C-terminal proteolytic
fragments 397–418 or 377–396 (VIRIP) on infection of PBMCs with R5- and X4-tropic viruses. HIV-1 replication was assessed by analysis of supernatant
p24 levels 7 d post-infection, and results are expressed relative to p24 levels in control infected cells treated with vehicle only. R5 and X4 virus
replication in PBMCs was significantly inhibited by VIRIP (p,0.0001, as determined by one-way ANOVA). (B) Effect of A-SAA on infection of PBMCs
with R5 or X4 viruses, or infection of MDDCs with an R5 virus, assessed as in (A), although p24 levels in MDDC supernatants were evaluated after a 4 d
rather than a 7 d infection period. Data from two MDDC infection experiments is shown, one using an A-SAA concentration range from 12.5mg–
100mg/ml, and the other from 0.5mg–8mg/ml. R5 virus replication in MDDCs was significantly inhibited by A-SAA in both experiments (p,0.0001, as
determined by one-way ANOVA). (C) Effect of CRP on infection of PBMCs with R5- or X4-tropic viruses, assessed as in (A). For all results, mean and
STDEV values are shown for triplicates per experiment.
doi:10.1371/journal.ppat.1000893.g006
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with a similar volume of 2% DMSO OptiMEM or plain
OptiMEM (vehicle only) to match the addition of inhibitor.
PBMCs were preincubated with inhibitors for 2 h prior to
infection, then were infected with R5 or X4 virus at a MOI of
0.01 for 16 h at 37uC in the presence of inhibitor. Excess virus and
inhibitor were washed out and cells were cultured for 7 d in R10
medium plus 50U ml
21 IL-2. Supernatants were harvested and
p24 levels were determined by ELISA (Advanced BioSciences
Laboratories, Inc., Kensington, MD). MDDCs were preincubated
with inhibitors for 1 h prior to infection at a MOI of 0.1 for 2 h at
37uC in the presence of inhibitor; and after washout of inhibitor
and excess virus, cells were cultured for 4 before reading out
supernatant p24 levels as described above. Statistical analysis of
the data from the viral inhibition assays was performed using a
one-way ANOVA.
Statistical analysis of ELISA data on plasma A-SAA levels
Two statistical tests were performed on transformed data from
the sample time-courses from the five control non-HIV-infected
plasma donors and the time points prior to D-15 in the time-
courses from HIV-infected plasma donors: a Wilcoxon test for a
two-group comparison (control vs. HIV-infected, p=0.28) and an
ANOVA test in a linear mixed model for the group difference
(p=0.4). As no significant differences were found between the
controls and pre-D-15 data from the HIV-infected subjects, both
were used to determine baseline A-SAA levels in the HIV-infected
subjects. Linear mixed-effects models were fit to these data to
estimate the subject-specific baseline level of A-SAA in each HIV-
infected individual. A-SAA values above the 90% upper prediction
bound was considered significantly elevated (see Fig. 3A and
S2A). A two-sided Binomial test was conducted to examine
whether the first elevation of A-SAA occurred significantly before
T0. Additional tests of associations between the timing of first A-
SAA elevation and three different parameters of viral replication
(viral reproductive rate R0, slope of viral ramp-up and the highest
recorded viral load) were also performed using linear models.
Supporting Information
Figure S1 Identification of A-SAA and complement C3 derived
peptides by tandem mass spectrometry. (A). LC-MS/MS analysis
of plasma donor sample 64012 time point T0+4 identified
precursor ion 1108.6 Da [M+2H]
2+ that corresponded to peptide
960–979 derived from complement C3 (Swissprot accession nr.
P01024). Identified b- and y- fragment ions are indicated. (B). LC-
MS/MS analysis of plasma donor sample 64012 time point T0+13
revealed precursor ion mass of 1090.4 Da [M+2H]
2+ that
corresponded to peptide 86–105 derived from A-SAA (Swissprot
accession nr. P02735).
Found at: doi:10.1371/journal.ppat.1000893.s001 (0.21 MB
PDF)
Figure S2 A-SAA levels as measured by ELISA in plasma panels
from 5 control plasma donors, 3 plasma donors acquiring HBV
infection and 3 donors acquiring HCV infection. (A). A-SAA levels
in plasma panels from five control non-HIV-infected plasma
donors. The solid circles show A-SAA protein levels. Subject-
specific background levels of A-SAA (dotted grey lines) and the
90% prediction interval (threshold for defining a significant
elevation, black lines) were calculated as described in the methods
section. (B). A-SAA levels in plasma panels from three HBV-
infected donors. In each graph, time is plotted relative to T200
(first time point where DNA levels are above 200 copies ml
21). A-
SAA protein levels are indicated by black squares and solid black
lines and HBV DNA levels by black triangles and dotted black
lines. (C). A-SAA levels in plasma panels from three HCV-infected
donors. In each graph, time is plotted relative to T600 (first time
point where RNA levels are above 600 copies ml
21). A-SAA
protein levels are indicated by black squares and solid black lines
and HCV RNA levels by black triangles and dotted black lines.
Found at: doi:10.1371/journal.ppat.1000893.s002 (0.33 MB
PDF)
Figure S3 Effect of A-SAA on HIV infection of MDDCs.
MDDCs were incubated with the indicated concentrations of A-
SAA and infected with R5 virus produced from the infectious
molecular HIV clone pNL4.3-Bal.ecto. Reverse transcriptase
levels were determined at 12, 24 and 48 h. Results are the
average of values from four sets of MDDCs generated from four
separate buffy coats. The error bars indicate 1 standard error
above and below the mean.
Found at: doi:10.1371/journal.ppat.1000893.s003 (0.13 MB
PDF)
Table S1 Elevated proteins present in AHI plasma prior or
during viremia identified by mass spectrometry
Found at: doi:10.1371/journal.ppat.1000893.s004 (0.03 MB XLS)
Text S1 Supporting Information
Found at: doi:10.1371/journal.ppat.1000893.s005 (0.03 MB
DOC)
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